Camgios Capsule 5 mg (Mavacamten)

Adult dose

The recommended starting dose of this drug is 5 mg orally once daily, with or without food. Swallow this drug whole with water. Do not open, crush, or chew the capsule. The patient's initial clinical response should be assessed 4 weeks after starting this drug. If the Valsalva LVOT gradient is < 20 mmHg, reduce the dose to 2.5 mg once daily. Otherwise, maintain the dose at 5 mg once daily. Subsequent follow-up visits should take place 8 and 12 weeks after starting treatment, with dose adjustments as needed (Figure 1). Until an individualized maintenance dose is reached, patients should be assessed at least every 12 weeks. After reaching an individualized maintenance dose, LVEF and Valsalva LVOT should be assessed at least every 6 months. If the patient's LVEF is < 50% at any visit, interrupt treatment for at least 4 weeks and until LVEF is ≥50%.

This drug can affect cardiac function and may decrease left ventricular ejection fraction, posing a risk of heart failure. Therefore, cardiac function must be verified with an echocardiogram before starting this medication, and the heart condition should be regularly monitored during treatment. Patients with cardiac function below a certain threshold should not take this medication, and if symptoms of heart failure occur or cardiac function worsens, treatment should be discontinued immediately. Additionally, since this drug is metabolized by certain liver enzymes (CYP2C19, CYP3A4), caution is needed when taking other medications that inhibit or activate these enzymes, as it may increase the risk of heart failure or reduce efficacy. In particular, it should not be taken together with strong CYP2C19 inhibitors or moderate to strong inducers of CYP2C19 or CYP3A4. This medication should not be given to pregnant women due to potential harm to the fetus, and women of childbearing potential should confirm pregnancy status before taking it and ensure effective contraception during and for at least 4 months after treatment. This drug may cause side effects such as dizziness or headache, necessitating caution when driving or operating machinery after taking it. Patients with severe impairment of kidney or liver function should take this medication cautiously, as its safety has not been fully established, and in some cases, its use is not recommended. In case of overdose, serious side effects, such as impaired cardiac function, may occur, requiring immediate medical attention, and measures to reduce absorption, such as the administration of activated charcoal, may be necessary. Patients taking this medication must inform their doctor of all drugs they are currently taking and always check for possible drug interactions. Finally, this medication is not recommended for use in children under 18 due to insufficient safety and efficacy data.

• Dizziness
• headache
• stress-induced cardiomyopathy
• syncope
• atrial fibrillation
• nasopharyngitis
• low back pain
• cough
• difficulty breathing
• fatigue

This drug should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1°C and 30°C.

Appearance

This drug is a hard capsule with an upper opaque yellow and a lower opaque white, filled with white to off-white powder, with '5mg' printed on the upper part and 'Mava' on the lower part.

Package unit

Blister - 28 capsules/box